KKR, a global investment firm, announced an agreement to invest in Catalio Capital Management, LP, a multi-strategy investment firm focused on breakthrough biomedical technology and innovative health care companies. The addition of new capital is expected to accelerate Catalio’s growth trajectory and talent acquisition, as well as anchor its investment strategies. Pursuant to the agreement, KKR…
Glympse Bio, a biotechnology company advancing the way diseases are understood, tracked, and treated, announced that it has raised $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases. The financing round was led…